Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.

@article{Etienne1991ImprovedBO,
  title={Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.},
  author={M. C. Etienne and G{\'e}rard Milano and N. Charles M.D. Ren{\'e} and Margherita Strolin Benedetti and Constantin Efthymiopoulos and M L Vo Van and Patrick Hurteloup and Philippe Montcuquet and Marc Paul Frenay and Moise Namer},
  journal={Journal of pharmaceutical sciences},
  year={1991},
  volume={80 12},
  pages={1130-2}
}
Medroxyprogesterone acetate (MPA) is widely used in the hormonal therapy of breast cancer. So far, oral formulations of MPA commercially available present a very low bioavailability, with a less than 10% extent of oral absorption. A new oral preparation of MPA has been recently developed. Based on a pilot study, an open, randomized, crossover trial has been… CONTINUE READING